Akero Therapeutics has hit a home run, reporting statistically significant results in two key 96-week metabolic dysfunction-associated steatohepatitis (MASH) analyses to send its stock up about 100%.

After 96 weeks, 39% of patients offered a 50-mg dose of efruxifermin showed a clinically meaningful reduction in liver fibrosis, or scarring, without other symptoms of MASH getting worse ...

Shares of Akero ascended by 115% in early Monday trading upon the news. MASH-associated cirrhosis patients “face a poor prognosis,” Catriona Yale, chief development officer at Akero, said on an ...

Yes, metabolic dysfunction-associated steatohepatitis (MASH) can result in cirrhosis of the liver. Formerly known as nonalcoholic steatohepatitis (NASH), MASH describes a type of metabolic ...